alpha2- and beta2-Adrenoreceptor-Mediated Ef_cacy of the Atypical Antidepressant Agomelatine Combined With Gabapentin to Suppress Allodynia in Neuropathic Rats With Ligated Infraorbital or Sciatic Nerve
Send a publication request

Publication request

Thank you for your interest in our product range and your request for this publication, which will be sent to you if the research team and the journal allow it. Our commercial team will contact you as soon as possible.

- Categories : Neuropathic pain , Pain , Publications

S M’Dahoma, M Poitevin, E Dabala et al

1 INSERM U894, Centre de Psychiatrie et Neurosciences, Paris, France, 2 Institut de Recherches Internationales Servier, Suresnes, France

Frontiers in Pharmacology

Previous data showed that neuropathic pain induced by mechanical lesion of peripheral nerves has speci_c characteristics and responds differently to alleviating drugs at cephalic versus extracephalic level. This is especially true for tricyclic antidepressants currently used for alleviating neuropathic pain in humans which are less effective against cephalic neuropathic pain. Whether this also applies to the antidepressant agomelatine, with its unique pharmacological properties as MT1/MT2 melatonin receptor agonist and 5-HT2B/5-HT2C serotonin receptor antagonist, has been investigated in two rat models of neuropathic pain. Acute treatments were performed 2 weeks after unilateral chronic constriction (ligation) injury to the sciatic nerve (CCI-SN) or the infraorbital nerve (CCI-ION), when maximal mechanical allodynia had developed in ipsilateral hindpaw or vibrissal pad, respectively, in Sprague–Dawley male rats. Although agomelatine (45 mg/kg i.p.) alone was inactive, co-treatment with gabapentin, at an essentially ineffective dose (50 mg/kg i.p.) on its own, produced marked antiallodynic effects, especially in CCI-ION rats. In both CCI-SN and CCI-ION models, suppression of mechanical allodynia by ‘agomelatine + gabapentin’ could be partially mimicked by the combination of 5-HT2C antagonist (SB 242084) + gabapentin, but not by melatonin or 5-HT2B antagonist (RS 127445, LY 266097), alone or combined with gabapentin. In contrast, pretreatment by idazoxan, propranolol or the _2 antagonist ICI 118551 markedly inhibited the anti-allodynic effect of ‘agomelatine+gabapentin’ in both CCI-SN and CCI-ION rats, whereas pretreatment by the MT1/MT2 receptor antagonist S22153 was inactive. Altogether these data indicate that ‘agomelatine+gabapentin’ is a potent anti-allodynic combination at both cephalic and extra-cephalic levels, whose action implicates alpha2- and beta2-adrenoreceptor-mediated noradrenergic neurotransmission.

BIOSEB Instruments Used:
Von Frey Filaments (Bio-VF-M)

Related products

Share this content